Hospitals urge regulators to halt drugmakers’ expanded 340B data policies
Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.
AI Summary: Hospitals and provider groups are urging federal regulators to halt new drugmaker policies that expand claims-data reporting tied to 340B discounts, calling the requirements unlawful and administratively burdensome. The dispute pits safety-net providers against manufacturers seeking program transparency — a classic tug-of-war with patients’ financial stakes caught in the middle.
Related Stories
Optum Rx/Caremark and FTC edge toward settlement in insulin case / 4 months
Tampa General sues Eli Lilly over pulled 340B discounts / 12 hrs
340B discounts face reform as profits outpace patient benefit / 2 months
AbbVie sues HHS over 340B patient definition and guidance / 3 months
Pharmacies prevail as Florida hospitals lose $2B opioid lawsuit / 5 wks
CMS tightens oversight of accrediting bodies and consulting limits / 24 days
RN turnover nearly doubled since pandemic, alarming hospital leaders / 27 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pfizer, FDA, Adolescent Health, Drug Pricing and look for the RSS link.
StackHealth Time Machine